Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity

Jose Carlos de Lima-Junior¹, Vitor W.M. Virginio¹, Filipe A. Moura^{1,2}, Adriana Bertolami³, Marcelo Bertolami³, Otavio R Coelho-Filho⁴, Ilaria Zanotti⁶, Wilson Nadruz⁴, Eliana Cotta de Faria⁵, Luiz Sergio F. de Carvalho^{1,4}, Andrei C Sposito^{1,4}

1. Laboratory of Atherosclerosis and Vascular Biology, Faculty of Medical Sciences, State University of Campinas, São Paulo, Brazil
2. Department of Cardiology, Brigham and Women's Hospital, Boston, New England, United States
3. Department of Dyslipidemia, Dante Pazzanese Cardiological Institute, São Paulo, Brazil
4. Department of Internal Medicine, Cardiology Division, Faculty of Medical Sciences, State University of Campinas, São Paulo, Brazil
5. Lipids Laboratory, Department of Clinical Pathology, Faculty of Medical Sciences, State University of Campinas, Sao Paulo, Brazil
6. Department of Food and Drug, University of Parma, Parma, Italy

To whom correspondence should be addressed. E-mail: andreisposito@gmail.com

Corresponding author:

Andrei C Sposito
Cardiology Division, State University of Campinas
13084-971, Campinas, São Paulo, Brazil
andreisposito@gmail.com

Running title: Excess weight and HDL functions

The authors declare no conflict of interest.

Keywords - atherosclerosis; cholesterol efflux; HDL metabolism; HDL; obesity

28 **Abbreviations:** ALT, alanine aminotransferase; ApoA-I, apolipoprotein A-I; AST,
 29 aspartate aminotransferase; CE, cholesteryl ester; CEC, Cholesterol efflux capacity; CETP,
 30 cholesteryl ester transfer protein; cIMT, carotid intima-media thickness; FC, free cholesterol;
 31 HL, hepatic lipase; HOMA2 % β , Homeostasis model assessment 2 of beta-cell function;
 32 HOMA2-IR, Homeostasis model assessment 2 of insulin resistance; HOMA2 %S, Homeostasis
 33 model assessment 2 of insulin sensitivity; HUVEC, human umbilical vein endothelial cells;
 34 LCAT, Lecithin-cholesterol acyltransferase activity; PL, phospholipids; LPL, Lipoprotein
 35 lipase; PON, paraoxonase; TC, total cholesterol; PLTP, phospholipids transfer protein; VCAM-
 36 1, vascular cell adhesion molecule-1.

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Abstract:**

52 **Objective:** Obesity-related decline in high-density lipoprotein (HDL) functions such as
 53 cholesterol efflux capacity (CEC) has supported the notion that this lipoprotein dysfunction may
 54 contribute for atherogenesis among obese patients. Besides, potentially other HDL protective
 55 actions may be affected with weight gain and these changes may occur even before the obesity
 56 range.

57 **Methods:** Lipid profile, body mass index (BMI), biochemical measurements, and
 58 carotid intima-media thickness (cIMT) were obtained in this cross-sectional study with 899
 59 asymptomatic individuals. HDL functions were measured in a subgroup (n=101).

60 **Results:** Individuals with increased HDL-C had an attenuated increase in cIMT with
 61 elevation of BMI. CEC, HDL-C, HDL size and HDL-antioxidant activity were negatively
 62 associated with cIMT. BMI was inversely associated with HDL-mediated inhibition of platelet
 63 aggregation and CEC, but surprisingly it was directly associated with the antioxidant activity.
 64 Thus, even in non-obese, non-diabetic individuals, increased BMI is associated with a wide
 65 change in protective functions of HDL, reducing CEC and increasing antioxidant activity. In
 66 these subjects, decreased HDL concentration, size or function are related to increased
 67 atherosclerotic burden.

68 **Conclusion:** Our findings demonstrate that in non-obese, non-diabetic individuals, the
 69 increasing values of BMI are associated with impaired protective functions of HDL and
 70 concomitant increase in atherosclerotic burden.

71
 72
 73
 74
 75
 76
 77

1. Introduction

Presently, one in three individuals with excess weight will die from cardiovascular disease (CVD)[1, 2]. In fact, both obesity (BMI >30 kg/m²) and overweight (BMI of 25 to <30 kg/m²) individuals are at increased risk of cardiovascular death as compared with those with BMI within the normal range (18.5 to <25 kg/m²)[3]. The proposed milieu for this interaction involves a spectrum of mechanisms in which phenotypic or functional changes in high-density lipoprotein (HDL) are involved [4].

The identification of HDL involvement in adiposopathy is not a recent issue. Since the metabolic syndrome was conceived, all clinical criteria for its diagnosis included low levels of plasma HDL-cholesterol (HDL-C) as a marker of metabolically, unhealthy obesity. In the mechanistic point of view, the combination of increased substrate, such as triglyceride-rich lipoproteins, and increased activity of HDL remodeling proteins, such as cholesteryl ester transfer protein (CETP), and hepatic lipase (HL), coexists in overweight individuals as a result of insulin resistance, promoting a reduction in HDL concentration, size and its content of apolipoproteins AI (ApoA-I). In addition, a decrease in the overall cholesterol efflux capacity (CEC) has been reported in obese subjects [5], despite the increased ABCA1-mediated cholesterol efflux[6].

Besides CEC, HDL also mediates several other anti-atherosclerotic mechanisms, such as antioxidant, anti-inflammatory activities and inhibition of platelet aggregation, whose extent is sensitive to phenotypic changes of the particles, such as those described above. If this is so, more than the reduced capacity as free cholesterol acceptor, an overall dysfunction in the HDL system may follow weight gain [7]. Furthermore, as the magnitude of these phenotypic changes in HDL occurs in parallel with the increase in BMI, it is possible that a cluster of particle dysfunctions occurs earlier with the weight gain, possibly even before the criterion for overweight. Hence, a metabolic legacy related to HDL may contribute to the future CVD risk. In order to shed some light on these gaps, we designed this study to evaluate the impact of BMI

on the interaction between HDL concentration and functions with atherosclerotic burden in pre-obese individuals.

2. Materials and methods

2.1. Cross-sectional study description

We evaluated a sample of 899 asymptomatic individuals who were seen in two primary care centers between 2008 and 2013: the outpatient clinic at Dante Pazzanese Institute of Cardiology, São Paulo (SP), Brazil, and governmental primary care centers of the city of Campinas, SP, Brazil. Inclusion criteria were: (1) no manifested atherosclerotic CVD; (2) no diagnosis of type 2 diabetes based on antidiabetic treatment, fast blood glycemia ≥ 126 mg/dL, glycated hemoglobin $\geq 6.5\%$ or glycemia ≥ 200 mg/dL on 120-minutes oral tolerance test and (3) age between 20 and 75 years old. We excluded individuals with (1) uncontrolled hyper (thyroid stimulating hormone (TSH) $< 0.41 \mu\text{UI/mL}$ or free thyroxine $> 1.8 \text{ ng/dL}$) or hypothyroidism (TSH $> 4.50 \mu\text{UI/mL}$ or free thyroxine $< 0.9 \text{ ng/dL}$); (2) antidiabetic medications; (3) liver disease, as indicated by ALT or AST over two times the upper limit; (4) urea $> 40 \text{ mg/dL}$; (5) glomerular filtration rate $\leq 60 \text{ mL/min/1.73m}^2$; (6) heart failure NYHA stage $\geq \text{III}$; (7) HIV positive or (8) withdrawal of informed consent. Patients underwent clinical examination, as well as biochemical analysis. Subclinical atherosclerosis was measured in all patients up to a month after being included. The study was approved by the local institutional ethical committee of the Instituto Dante Pazzanese de Cardiologia (registration number 3852/2009). It is also registered at ClinicalTrials.Gov by the identification NCT02487615. All patients provided written and informed consent forms before taking part in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

A sub-analysis testing functions and characteristics of HDL was performed in consecutive sample of 101 individuals from the enrolled participants in the governmental primary care centers of the city of Campinas. The study was approved by the local institutional ethical committee of the Hospital das Clínicas of the State University of Campinas (registration number 1260/2010). It is registered at ClinicalTrials.Gov by the identification NCT02106013.

131 All patients provided written and informed consent forms before taking part in the study. The
132 study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

133 **2.2. Biochemical analysis**

134 Blood samples were drawn after a 12-hour fasting period. The following biochemical
135 measurements were performed: triglycerides, total cholesterol, HDL-C, creatinine, c-reactive
136 protein (CRP), insulin, glucose, and insulin. LDL-C was calculated using Friedewald's
137 equation. Glomerular filtration rate was calculated by the CKD-EPI equation. HOMA2 % S,
138 HOMA2-IR and HOMA2 β were calculated using computer models [8].

139 **2.3. Carotid artery ultrasound**

140 Carotid Doppler ultrasound was performed using high-resolution Vivid 7 ultrasound
141 (GE, USA) and high-frequency linear transducer (9 MHz) with automatic border recognizer
142 detection as described previously in Bertolami et al [9]. Briefly, the cIMT was obtained by
143 means of image processing of B-mode ultrasonograms of the right and left automatic
144 measurement. High-resolution B-mode ultra-sonographic imaging was performed initially
145 evaluating the common carotid artery with antero-oblique insonation above the clavicle and
146 alongside the internal carotid artery, as standardized procedure[10]. Measurement of cIMT was
147 obtained 20 mm proximally from the carotid bifurcation as the distance between the lumen-
148 intima interface and the media-adventitia interface[11].

149 **2.4. Lipoprotein isolation**

150 LDL was isolated from a pool of normolipidemic sera from 20 volunteers, through
151 sequential ultracentrifugation using a Beckman L8-M ultracentrifuge (Beckman Coulter Inc.,
152 Palo Alto, USA), with a 75Ti fixed angle rotor (Havel, 1955 #11). HDL was isolated from each
153 study participant through density gradient ultracentrifugation[12] with the use of a SW41Ti
154 rotor. Isolated lipoproteins were extensively dialyzed against EDTA-free PBS for 24h, at 4°C, in
155 a dark room. All assays were performed in freshly isolated lipoproteins that were kept at 4°C for
156 a maximum period of 15 days.

157 **2.5. HDL chemical composition and molar concentration measurements**

HDL chemical composition was measured using commercially available enzymatic kits, in the microplate reader Power Wave XS (BioTek®, Winooski, USA). Total proteins (Pierce™ BCA Protein Assay Kit, Thermo Scientific, Rockford, USA), TC (CHOD-PAP, total cholesterol, Roche Diagnostics® reagents, Mannheim, Germany), FC (Free Cholesterol E, Wako Chemicals, Richmond, USA), PL (Phospholipids C, Wako Chemicals, Richmond, USA), TG (TG, GPO-PAP, Roche Diagnostics® reagents, Mannheim, Germany) and ApoA-I (TINA QUANT APOA1 V2, Roche Diagnostics® reagents, Mannheim, Germany) were measured, while CE was calculated according to the following formula: $(TC-FC) \times 1.67$ [12]. The relative content of ApoA-I (HDL-ApoA-I) or lipids in HDL was calculated based on their proportion to the total mass of HDL, calculated as the sum of FC, PL, TG, CE, and total proteins. HDL molar concentration was estimated based on particle total mass and molecular weight[12].

2.6. HDL physical-chemical characterization

HDL particle size was determined using dynamic light scattering, in a Nanotracer Particle Size Analyser 250 (Microtrac Inc., Montgomeryville, USA)[13]. Zeta potential was determined in HDL diluted 1:10 in KCl 10mM, using laser Doppler micro-electrophoresis, in the Zetasizer Nano ZS (Malvern Instruments, Malvern, UK).

2.7. Determination of proteins involved in HDL metabolism

CETP and PLTP activities were measured using exogenous radiometric assays, as previously described[14, 15]. LPL and HL activities were measured in fasted post-heparin plasma samples, collected 15min after the intravenous administration of heparin (100U/kg body weight), in an assay based on fatty acid release from a radiolabeled triolein emulsion[16]. LCAT activity was determined using recombinant HDL, according to standardized method [17]. PON activity was measured using paraoxon (diethyl-p-nitrophenylphosphate, Sigma, St. Louis, MO, USA) as substrate [18].

2.8. HDL antioxidant activity

HDL antioxidant activity was measured in a kinetic fluorimetric assay adapted from Navab et al[19]. Oxidation was monitored as changes in the fluorescence intensity of 2',7'-dichlorofluoresceine (DCFH). For the antioxidant activity assays, LDL (final concentration,

186 20mgTC/dL) and CuSO₄ (final concentration, 0.5μM) were added to DCFH-containing tubes
 187 (final concentration, 2mg/mL), followed by the addition or not of HDL (final concentration,
 188 15mg total mass/dL). The volume was adjusted to 100μL with Chelex treated-PBS and the
 189 reaction mixture transferred onto a black 96-well microplate. The plate was covered with an
 190 optical adhesive cover to avoid evaporation and incubated at 37°C. Fluorescence intensity was
 191 measured over 24h with 15-minute intervals in a fluorescence microplate reader (Spectra Max
 192 M5; Molecular Devices, Sunnyvale, USA) at an excitation wavelength of 485nm, emission
 193 wavelength of 540 nm, and cut-off of 530nm. Results of antioxidant activity are presented as the
 194 percentage of inhibition of LDL oxidation in the presence of each subject's HDL when
 195 compared to control wells (LDL alone).

196 **2.9. HDL anti-inflammatory activity**

197 HDL's anti-inflammatory activity was measured in HUVEC in an assay adapted from
 198 Besler et al[20]. Cells were cultured in RPMI 1640 medium containing 10% fetal calf serum,
 199 penicillin, and streptomycin and maintained in a 5% CO₂ incubator at 37°C. After reaching
 200 confluence, they were plated in 24-well culture plate (3 x 10⁵ cells/well, and incubated with
 201 TNF-α (1ng/mL), with or without HDL (50μg ApoA-I/mL) for three hours. The culture media
 202 were collected and stored at -80°C. Due to the low VCAM-1 concentrations, samples were
 203 concentrated using the Amicon® Ultra Centrifugal Filters, 50K (Millipore, Massachusetts,
 204 USA) and then VCAM-1 concentrations were measured using the Human VCAM-1 ELISA Kit
 205 (Cat number ECM340, Millipore, Massachusetts, USA). Results are expressed as the percentage
 206 of decrease in VCAM-1 concentrations in the wells incubated with HDL when compared to the
 207 control wells without HDL.

208 **2.10. Cholesterol efflux capacity (CEC) assay**

209 Global cellular CEC was performed using J774 macrophages enriched with acetylated
 210 LDL and ¹⁴C-cholesterol and HDL as the cholesterol acceptor[21]. In summary, J774
 211 macrophages were cultured in RPMI 1640 medium containing 10% fetal calf serum, penicillin,
 212 and streptomycin and maintained in a 5% CO₂ incubator at 37°C. After reaching confluence,
 213 cells were plated in a 96-well plate (1.25 x 10⁵ cells/well, and enriched with acetylated LDL (50

214 $\mu\text{g/mL}$) and ^{14}C -free cholesterol ($0.3\mu\text{Ci} / \text{mL}$). After 48h, cells were washed with PBS
215 containing fatty acid-free albumin (FAFA) and equilibrated with DMEM containing FAFA for
216 24 hours. The cells were then washed twice and incubated with HDL ($50\mu\text{g ApoA-I/mL}$) for 8
217 hours. Media were collected and the radioactivity measured in a beta-scintillation counter. Cells
218 were rinsed twice with cold physiologic saline and the intracellular lipids extracted with hexane:
219 isopropanol (3:2, v/v). Solvent was evaporated and radioactivity measured. The percentage of
220 ^{14}C -CEC was calculated as (^{14}C -cholesterol in the medium/ ^{14}C -cholesterol in cells+medium)
221 $\times 100$.

222 **2.11. HDL-mediated platelet aggregation inhibition**

223 HDL ability to inhibit platelet aggregation was measured as described by Valiyaveetil
224 et al[22]. HDL (0.8mg protein/mL) was mildly oxidized by dialysis against PBS + $5\mu\text{M CuSO}_4$,
225 for 24h at 37°C . Citrated blood was drawn from a healthy donor and platelet-rich plasma (PRP)
226 obtained by centrifugation at 800rpm for 15 minutes. PRP was then incubated with native or
227 oxidized HDL (0.5 mg/mL) for 30 minutes at 37°C . Platelet aggregation was monitored using a
228 Lumi-Aggregometer type 500 VS (Chrono-log, Havertown, USA) for 6 minutes after the
229 addition of ADP ($5\mu\text{M}$). Results are expressed as percentage of the inhibition of platelet
230 aggregation induced by oxidized compared to native HDL.

231 **2.12. Statistical analysis**

232 The distribution of all variables was tested with Kolmogorov-Smirnov test. Jonckheere-
233 Terpstra trend in one-tail test was used to evaluate demographic, clinical variables and HDL
234 characterization among three groups clustered using BMI and expressed as median and
235 interquartile range. ANCOVA was used to perform comparisons among groups involving
236 enzymatic components of HDL adjusted for age, sex, and HOMA2 %S. Generalized linear
237 models with type III sums of squares were used to assess interactions of BMI within the
238 association between HDL functions and cIMT, the only outcome, adjusted for age, sex, HDL-C,
239 BMI, and HOMA2 %S. HDL functions and HDL-C were modeled with generalized linear
240 regression. The BMI effect on the cIMT among six HDL functions (HDL-C, HDL size,
241 antioxidant activity, CEC, HDL-mediated platelet inhibition, and anti-inflammatory activity)

was evaluated with the use of interaction tests. We used complete case analysis to handle missing data. To construct the 3D surface plot 1, we included only HDL-C values between 40mg / dL and 100mg / dL; HDL size between 7.0 nm and 9.5 nm; CEC between 8% and 20%; antioxidant activity between 0 and 100%. For the remainder of the regression analyzes, we used the entire sample size of the sub-sample of 99 individuals. Two-sided $p \leq 0.05$ were considered to indicate statistical significance. Analyses were performed using IBM SPSS[®] version 21.0 statistical software. Scatter plot was performed using GraphPad Prism version 7.0 for Mac, GraphPad Software, La Jolla California USA, www.graphpad.com". Polynomial splines were used to evaluate the relation between BMI or carotid IMT vs CEC or Antioxidant activity or a compound variable, after transforming CEC and Antioxidant activity into positive z-scores. The compound variable (Z-Efflux + Z-Antioxidant activity) was defined by the sum of z-scores for CEC and antioxidant activity. In order to avoid overfitting, we excluded extreme values at x-axis (<5th percentile and >95th percentile) and smoothing parameters for polynomial derivation (degrees of freedom [df] and lambda) were defined after cross validation. Spline curves were performed in R software, version 3.2.1 (R Foundation for Statistical Computing). We used MATLAB[®] (version 4.10, The MathWorks, Inc, Apple Hill Drive Natick, MA) to fit a 3D curve using second polynomial least square surface.

259

260 **3. Results**

261 ***3.1. Overall study participants characteristics***

262 The baseline characteristics of participants are shown in Table 1 stratified by BMI status
263 (n=899). The female gender prevailed among the participants and BMI values were associated
264 with waist circumference, increased cIMT and impaired metabolic parameters; *i.e.* lower HDL-
265 C, Apo-AI and HOMA2%S, as well as higher triglycerides, insulin and fasting glucose.
266 Similarly, a stepped increase in LDL-C and total cholesterol was also noted with increasing
267 BMI.

268 ***3.2. Association between BMI, HDL-C and cIMT***

269 In the whole studied sample (n=899), multivariable linear regression analyses adjusted for
 270 BMI, age, gender, and plasma insulin or HOMA2-IR, confirmed the association between cIMT
 271 and HDL-C ($\beta=-0.11$; 95%CI=-0.020;0.000; $p=0.03$) and identified the existence of a
 272 significant interaction of BMI upon this association ($\beta=-1.80$; $p<0.0001$). To visualize the
 273 pattern for such BMI interaction, 3D surface plots were applied based on second polynomial
 274 least square regression (Figure 1). As shown in the Figure 1A, in subjects with increased BMI,
 275 reduced HDL-C levels were associated with increased cIMT. In contrast, in those individuals
 276 with reduced BMI, no clear association was found between HDL-C and cIMT. In order to
 277 provide a deeper assessment of this interaction, a broad spectrum of HDL functions was
 278 investigated in a subgroup of these individuals. As it would be expected, an inverse association
 279 was found between BMI and HDL-C (Spearman's rho -0.028, $p < 0.0001$) and HDL size
 280 (Spearman's rho -0.175, $p < 0.0001$).

281 *3.3. Association between BMI, HDL functions and cIMT in the subgroup analyses*

282 The subgroup characteristics are shown on Table 2. In the subgroup, we found a stepped
 283 decrease of total HDL mass, HDL size, and HDL content in triglyceride, free cholesterol,
 284 cholesteryl ester, and phospholipid across BMI categories (Table 3). PON activity adjusted for
 285 the total number of HDL particles, *i.e.* PON/HDL-C ratio, increased in parallel with BMI
 286 categories. There was no relation between BMI categories and activities of PLTP, LCAT, HL or
 287 LPL (Table 3).

288 In line with previous studies, as shown in Figure 2A (linear beta -0.38, polynomial
 289 $R^2=0.19$, $p=0.001$; Spearman's rho -0.32, $p<0.001$), we reported a progressive decline in CEC
 290 as BMI increases. In contrast, we found a progressive increase in HDL antioxidant activity
 291 which was proportional and reciprocal as compared with CEC (linear beta +1.38, polynomial
 292 $R^2=0.12$, $p=0.04$) (Figure 2B). Both changes were mainly mediated by the HDL size which is
 293 inversely related to weight gain. Based on this assumption, the compound variable of z-
 294 transformed efflux plus antioxidant activity should remain approximately constant as HDL size
 295 changes due to excess weight (p value 0.75) (Figure 2C). Increasing values of the compound

variable were associated lower carotid IMT (linear beta -0.10, polynomial $R^2=0.26$, $p<0.001$) (Figure 2D). Still, correlation analyses were made between BMI and HDL functions. An inverse association was also found with HDL-mediated platelet inhibition (Spearman's rho -0.157, $p<0.03$). No correlation was found between BMI and HDL anti-inflammatory activity (Spearman's rho -0.009, $p<0.904$) nor between each of the HDL functions.

Since both the abundance of substrate, *i.e.* triglyceride-rich lipoproteins, and the activities of transport proteins are potentially involved in the effect of excess weight on HDL phenotype, multivariate linear regression models were applied to estimate the influence of intravascular HDL-remodeling proteins, *i.e.* CETP, LPL, HL, LCAT and PLTP on HDL size. CETP ($\beta=-0.12$; 95%CI=-0.30;-0.01; $p=0.030$), HL ($\beta=-0.28$; 95%CI=-0.35;-0.12; $p<0.0001$) and LCAT ($\beta=-0.36$; 95%CI=-0.28;-0.13; $p<0.0001$) were drivers for HDL size. HDL size was also associated with plasma triglycerides ($\beta=-0.17$; 95%CI=-0.06;-0.02; $p<0.001$), HOMA2-IR ($\beta=0.21$; 95%CI=0.01;0.42; $p=0.001$), PON activity/HDL-C ($\beta=-0.33$; 95%CI=-0.47;-0.13; $p<0.0001$) and HDL-mediated antioxidant activity ($\beta=-0.70$; 95%CI=-0.81;-0.12; $p=0.009$). Association was found between HOMA2-IR and HDL-mediated antioxidant activity ($\beta=-2.1$; 95%CI=-3.66;-0.60; $p=0.007$).

In order to estimate the association between HDL functions and cIMT, we used multiple linear regression with adjustments for the following confounders (BMI, age, sex, HDL-c and insulin), which were selected based on univariate significance or clinical relevance (age, sex) (Table 4). We observed a negative association between CEC and cIMT, which remained significant after initial adjustment for the same confounders above, or even after adjustment for HDL size ($\beta=-0.18$; 95%CI=-0.138; -0.011; $p=0.02$), antioxidant activity ($\beta=-0.19$; 95%CI=-0.003;0.000; $p=0.04$) and PON activity/HDL-C ($\beta=-0.16$; 95%CI=-0.065;-0.002; $p=0.02$). The antioxidant activity of HDL was also inversely related to cIMT. Anti-inflammatory activity, PON activity/HDL-C and HDL-mediated platelet inhibition were not associated with cIMT in an adjusted model.

Interactions of BMI were found within the linear associations between cIMT and CEC ($p=0.03$), and cIMT and antioxidant activity ($p=0.04$). Although the 95% CI suggests a tendency

324 towards a moderating effect of the BMI on the association between HDL size and cIMT, this
325 interaction did not reach statistical significance ($p=0.13$) (Fig. 1B). As displayed in Fig 1C, the
326 inverse association between CEC and cIMT seems to increase in parallel with BMI values. In
327 contrast, as shown in Fig 1D, the inverse association between cIMT and antioxidant activity of
328 HDL increases with increasing BMI. In fact, the correlation between cIMT and antioxidant
329 activity is greater in individuals with BMI above the median (23.6 kg/m^2) ($r=-0.33$; $p=0.037$)
330 than in their counterparts ($r=-0.2$; $p=0.05$) while the correlation between CEC and cIMT is equal
331 in both subgroups (above, $r=-0.28$; $p=0.042$; below, $r=-0.28$; $p=0.016$).

332

333 4. Discussion

334

335 Recent data have shown that the predictive value of HDL-C for estimating the risk of
336 cardiovascular events declines after CVD manifestation[23]; a failure that has been attributed to
337 the increased generation of dysfunctional HDL in a setting of chronic or acute disease. As
338 pointed out in subjects with CVD, we hypothesized that excess weight may influence the
339 relationship between HDL-C and the risk of atherosclerotic disease. After confirming this
340 hypothesis, we moved forward investigating whether more subtle changes in the HDL system
341 could occur in overweight individuals and whether this could justify a change in the association
342 pattern between HDL-C and atherosclerotic disease. Taken together, our findings revealed the
343 following evidence: (i) the pattern of association between HDL-C and cIMT differs according to
344 the presence or absence of excess weight; (ii) increased BMI is associated with the simultaneous
345 change of multiple anti-atherosclerotic functions of HDL, including CEC and antioxidant
346 activity; (iii) the existing association between excess weight and carotid atherosclerotic burden
347 is in part attributable to HDL dysfunction; and (iv) HDL-mediated inhibition of platelet
348 aggregation declines with excess weight.

349 To the best of our knowledge, only few studies have previously assessed the impact of
350 body weight on HDL function in non-obese individuals and none used a simultaneous
351 assessment of multiple functions. In this clinical setting, CEC has been the main HDL function

assessed, which was investigated in interventional [3], case-control[24] and cross-sectional [5] studies. In a large nested case-control study from the EPIC-Norfolk cohort, for example, discrete changes in BMI in the overweight range was inversely correlated with CEC [24]. On this specific aspect, our results are in line with previous studies.

Weight gain promotes a wide range of metabolic changes, among which insulin resistance is the cornerstone for CVD risk. As a result of insulin resistance, for example, there is an increase in the fatty acid efflux and in the activities of CETP and HL leading to a reduction in HDL size, an increase in the ApoA-I catabolic rate and a reduction in CEC[5, 25, 26]. In contrast with the evidence in obese subjects [27-29], our study did not identify changes in CETP and HL activities across BMI categories although their activities were associated with HDL size change. Thus, at this stage of excess weight, the biochemical and size changes in HDL particles is more likely a consequence of increased substrate for HDL particle remodeling, *i.e.* increased plasma concentration of triglyceride-rich lipoproteins.

These changes in the HDL system have traditionally been reported as a component cause for the increased risk of CVD in obese individuals[30]. In those who are overweight but below the obesity threshold, we revealed a similar scenario, *i.e.* insulin resistance inversely relates with overweight, HDL size and CEC. It is interesting to note that these changes occurred even before the threshold for overweight as defined by World Health Organization (WHO). Thus, according to previous translational studies[31] or actuarial analyzes based on observational cohorts[32], our data support the concept that the threshold for pathogenic body mass is probably below the WHO definition.

Although it is clear that there is functional impairment, it is plausible that the change in the HDL phenotype would have an adaptive biological purpose motivated by the chronic increase of oxidative stress and by low-grade systemic inflammation. Similar reduction of HDL size has been reported in individuals who exhibit acute phase response, such as in myocardial infarction[33] and sepsis[34]. In these conditions, the reduction of HDL size is associated with a greater capacity to mitigate the oxidative stress. In agreement with this and consistent with previous studies, HDL size was inversely associated with increased antioxidant and PON

activities[35]. Interestingly, the predominance of small HDL (7.3-8.2 nm) in this cohort was associated with an attenuated impact of BMI on cIMT. Hence, overweight-induced remodeling in HDL simultaneously promoted the reduction of an anti-atherosclerotic mechanism, i.e. CEC, and the increase of another, i.e. antioxidant activity, suggesting a biological response of the HDL system to the predominant pro-atherosclerotic stimulus. Besides, the present study shows that estimates of the magnitude of HDL participation in the CVD risk in excess weight are naturally imprecise unless a broad range of anti-atherosclerotic functions is simultaneously investigated.

Obesity is clearly shown to be a prothrombotic state resulting from a combination of increased thrombin generation, platelet hyperactivity and decreased fibrinolysis[36]. Increased platelet reactivity is the result of the interaction between multiple characteristics grouped into obesity, including inflammation, oxidative stress, insulin resistance and adiposopathy with change in adipokine secretion pattern. Our study added to this state of knowledge, a new mechanism of imbalance in platelet activity; inhibition of HDL-mediated platelet aggregation was inversely associated with BMI. This finding should be considered in the set of prothrombotic changes of excess weight and as one of the mechanisms by which there is an increase in the incidence of cardiovascular events in these individuals.

Among the main limitations in the present study lies the fact that it is based on a cross-sectional design. In addition, due to the intensive laborious methodology involved in studying a full breadth of HDL function and metabolic pathways, we may have not been able to maintain the desired statistical power obtained as when the entire studied population was analyzed. In spite of this, it does provide us a unique opportunity to evaluate the association between excess weight and the HDL system early in the spectrum of metabolic derangement and atherogenesis. In fact, this may especially be true given the low rates of insulin resistance and more favorable lipid profile and systemic inflammatory activity of our study's participants.

In conclusion, our study indicates that higher BMI, even in non-obese, non-diabetic individuals, is associated with decreased function of several protective activities of HDL. In individuals with increased BMI, HDL dysfunction is directly associated with increased

408 atherosclerotic burden. Antioxidant activity is found to be an exception increasing with BMI
409 and it partially attenuated the atherosclerotic burden.

410 **Declaration of interest:** The authors declare no conflict of interest.

411 **Funding** The study was supported by São Paulo Research Foundation (FAPESP 2010/00201-8
412 and FAPESP 2006/60585-9 and CNPq (471380/2008-13). JCLJ was supported by a doctoral
413 grant from Coordination for the Improvement of Higher-Level Education Personnel (Capes
414 grant number PROEX0092045). NBP was supported by a doctoral grant (number 2012/01645-
415 2) from the Foundation for Research Support of the State of Sao Paulo (FAPESP). Prof Sposito
416 was supported by a fellowship grant of productivity in research from the National Council for
417 Scientific and Technological Development (CNPq) (grant number 301465/2017-7).

418 **Author contribution statement:** Jose Carlos de Lima-Junior drafted the manuscript and
419 participated on the analysis of the data, Vitor W.M. Virginio participated on the experiments,
420 Filipe A. Moura participated on the drafting of the manuscript and analysis of the data, Adriana
421 Bertolami participated on the experiments, Marcelo Bertolami participated critically reviewing
422 the manuscript, Wilson Nadruz participated critically reviewing the manuscript, Eliana Cota de
423 Faria participated on the experiments and analysis of the data, Ilaria Zanotti participated
424 critically reviewing the manuscript, Luiz Sergio F. de Carvalho participated on the analysis of
425 the data and critically reviewing the manuscript, Andrei C Sposito participated on the analysis
426 of the data and critically reviewing the manuscript

427 **Acknowledgements.** We thank Natalia B. Panzoldo from the University of Campinas for
428 technical assistance in HDL functions experiments.

429

430

431 5. References

- 432 [1] D.K. Tobias, A. Pan, C.L. Jackson, E.J. O'Reilly, E.L. Ding, W.C. Willett, J.E. Manson, F.B. Hu,
433 Body-mass index and mortality among adults with incident type 2 diabetes, *N Engl J Med*
434 370(3) (2014) 233-44.
- 435 [2] A. Afshin, M.H. Forouzanfar, M.B. Reitsma, P. Sur, K. Estep, A. Lee, L. Marczak, A.H.
436 Mokdad, M. Moradi-Lakeh, M. Naghavi, J.S. Salama, T. Vos, K.H. Abate, C. Abbafati, M.B.
437 Ahmed, Z. Al-Aly, A. Alkerwi, R. Al-Raddadi, A.T. Amare, A. Amberbir, A.K. Amegah, E. Amini,
438 S.M. Amrock, R.M. Anjana, J. Ärnlöv, H. Asayesh, A. Banerjee, A. Barac, E. Baye, D.A. Bennett,
439 A.S. Beyene, S. Biadgilign, S. Biryukov, E. Bjertness, D.J. Boneya, I. Campos-Nonato, J.J. Carrero,
440 P. Cecilio, K. Cercy, L.G. Cioabanu, L. Cornaby, S.A. Damtew, L. Dandona, R. Dandona, S.D.
441 Dharmaratne, B.B. Duncan, B. Eshrati, A. Esteghamati, V.L. Feigin, J.C. Fernandes, T. Fürst, T.T.
442 Gebrehiwot, A. Gold, P.N. Gona, A. Goto, T.D. Habtewold, K.T. Hadush, N. Hafezi-Nejad, S.I.
443 Hay, M. Horino, F. Islami, R. Kamal, A. Kasaeian, S.V. Katikireddi, A.P. Kengne, C.N.
444 Kesavachandran, Y.S. Khader, Y.H. Khang, J. Khubchandani, D. Kim, Y.J. Kim, Y. Kinfu, S. Kosen,
445 T. Ku, B.K. Defo, G.A. Kumar, H.J. Larson, M. Leinsalu, X. Liang, S.S. Lim, P. Liu, A.D. Lopez, R.
446 Lozano, A. Majeed, R. Malekzadeh, D.C. Malta, M. Mazidi, C. McAlinden, S.T. McGarvey, D.T.
447 Mengistu, G.A. Mensah, G.B.M. Mensink, H.B. Mezgebe, E.M. Mirrakhimov, U.O. Mueller, J.J.
448 Noubiap, C.M. Obermeyer, F.A. Ogbo, M.O. Owolabi, G.C. Patton, F. Pourmalek, M. Qorbani, A.
449 Rafay, R.K. Rai, C.L. Ranabhat, N. Reinig, S. Safiri, J.A. Salomon, J.R. Sanabria, I.S. Santos, B.
450 Sartorius, M. Sawhney, J. Schmidhuber, A.E. Schutte, M.I. Schmidt, S.G. Sepanlou, M.
451 Shamsizadeh, S. Sheikbahaei, M.J. Shin, R. Shiri, I. Shiue, H.S. Roba, D.A.S. Silva, J.I. Silverberg,
452 J.A. Singh, S. Stranges, S. Swaminathan, R. Tabarés-Seisdedos, F. Tadese, B.A. Tedla, B.S.
453 Tegegne, A.S. Terkawi, J.S. Thakur, M. Tonelli, R. Topor-Madry, S. Tyrovolas, K.N. Ukwaja, O.A.
454 Uthman, M. Vaezghasemi, T. Vasankari, V.V. Vlassov, S.E. Vollset, E. Weiderpass, A.
455 Werdecker, J. Wesana, R. Westerman, Y. Yano, N. Yonemoto, G. Yonga, Z. Zaidi, Z.M. Zenebe,
456 B. Zipkin, C.J.L. Murray, G.O. Collaborators, Health Effects of Overweight and Obesity in 195
457 Countries over 25 Years, *N Engl J Med* 377(1) (2017) 13-27.
- 458 [3] A.A. Khan, P.A. Mundra, N.E. Straznicki, P.J. Nestel, G. Wong, R. Tan, K. Huynh, T.W. Ng,
459 N.A. Mellett, J.M. Weir, C.K. Barlow, Z.H. Alshehry, G.W. Lambert, B.A. Kingwell, P.J. Meikle,
460 Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-
461 Density Lipoprotein Functionality in Metabolic Syndrome, *Arterioscler Thromb Vasc Biol* 38(2)
462 (2018) 438-447.
- 463 [4] F.M. Sacks, M.K. Jensen, From High-Density Lipoprotein Cholesterol to Measurements of
464 Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in
465 Cardiovascular Disease, *Arterioscler Thromb Vasc Biol* 38(3) (2018) 487-499.
- 466 [5] T. Sasahara, P. Nestel, N. Fidge, D. Sviridov, Cholesterol transport between cells and high
467 density lipoprotein subfractions from obese and lean subjects, *J Lipid Res* 39(3) (1998) 544-54.
- 468 [6] N. Attia, N. Fournier, B. Védie, M. Cambillau, P. Beaune, O. Ziegler, A. Grynberg, J.L. Paul, B.
469 Guerci, Impact of android overweight or obesity and insulin resistance on basal and
470 postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities, *Atherosclerosis*
471 209(2) (2010) 422-9.
- 472 [7] A.C. Sposito, HDL metrics, let's call the number thing off?, *Atherosclerosis* 251 (2016) 525-
473 527.
- 474 [8] J.C. Levy, D.R. Matthews, M.P. Hermans, Correct homeostasis model assessment (HOMA)
475 evaluation uses the computer program, *Diabetes Care* 21(12) (1998) 2191-2.
- 476 [9] A. Bertolami, J.C. de Lima-Júnior, R.M. Cintra, L.S. Carvalho, C.C. Gonzaga, M.L. Sulzbach,
477 A.C.G.P. Petisco, J.E.M. Barbosa, A.A. Faludi, J. Plutzky, M.C. Bertolami, A.C. Sposito,
478 Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in
479 overweight subjects, *Clin Endocrinol (Oxf)* (2017).

480 [10] J.H. Stein, C.E. Korcarz, R.T. Hurst, E. Lonn, C.B. Kendall, E.R. Mohler, S.S. Najjar, C.M.
 481 Rembold, W.S. Post, F. American Society of Echocardiography Carotid Intima-Media Thickness
 482 Task, Use of carotid ultrasound to identify subclinical vascular disease and evaluate
 483 cardiovascular disease risk: a consensus statement from the American Society of
 484 Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for
 485 Vascular Medicine, Journal of the American Society of Echocardiography : official publication
 486 of the American Society of Echocardiography 21(2) (2008) 93-111; quiz 189-90.
 487 [11] M.W. Lorenz, S. von Kegler, H. Steinmetz, H.S. Markus, M. Sitzer, Carotid intima-media
 488 thickening indicates a higher vascular risk across a wide age range: prospective data from the
 489 Carotid Atherosclerosis Progression Study (CAPS), Stroke 37(1) (2006) 87-92.
 490 [12] M.J. Chapman, S. Goldstein, D. Lagrange, P.M. Laplaud, A density gradient ultracentrifugal
 491 procedure for the isolation of the major lipoprotein classes from human serum, J Lipid Res
 492 22(2) (1981) 339-58.
 493 [13] E.S. Lima, R.C. Maranhao, Rapid, simple laser-light-scattering method for HDL particle
 494 sizing in whole plasma, Clin Chem 50(6) (2004) 1086-8.
 495 [14] L. Lagrost, Determination of the mass concentration and the activity of the plasma
 496 cholesteryl ester transfer protein (CETP), Methods Mol Biol 110 (1998) 231-41.
 497 [15] M. Jauhainen, C. Ehnholm, Determination of human plasma phospholipid transfer protein
 498 mass and activity, Methods 36(2) (2005) 97-101.
 499 [16] C. Ehnholm, T. Kuusi, Preparation, characterization, and measurement of hepatic lipase,
 500 Methods Enzymol 129 (1986) 716-38.
 501 [17] J.W. Chisholm, A.K. Gebre, J.S. Parks, Characterization of C-terminal histidine-tagged
 502 human recombinant lecithin:cholesterol acyltransferase, J Lipid Res 40(8) (1999) 1512-9.
 503 [18] D.Z. Scherrer, V.H. Zago, I.C. Vieira, E.S. Parra, N.B. Panzoldo, F. Alexandre, R. Secolin, J.
 504 Baracat, E.C. Quintão, E.C. Faria, p.Q192R SNP of PON1 seems not to be Associated with
 505 Carotid Atherosclerosis Risk Factors in an Asymptomatic and Normolipidemic Brazilian
 506 Population Sample, Arq Bras Cardiol 105(1) (2015) 45-52.
 507 [19] M. Navab, S.Y. Hama, G.P. Hough, G. Subbanagounder, S.T. Reddy, A.M. Fogelman, A cell-
 508 free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating
 509 oxidized phospholipids, J Lipid Res 42(8) (2001) 1308-17.
 510 [20] C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanoto, D.M. Shih, A. Chroni, K.
 511 Yonekawa, S. Stein, N. Schaefer, M. Mueller, A. Akhmedov, G. Daniil, C. Manes, C. Templin, C.
 512 Wyss, W. Maier, F.C. Tanner, C.M. Matter, R. Corti, C. Furlong, A.J. Lusis, A. von Eckardstein,
 513 A.M. Fogelman, T.F. Luscher, U. Landmesser, Mechanisms underlying adverse effects of HDL
 514 on eNOS-activating pathways in patients with coronary artery disease, J Clin Invest 121(7)
 515 (2011) 2693-708.
 516 [21] A. Machado-Lima, R.T. Iborra, R.S. Pinto, C.H. Sartori, E.R. Oliveira, E.R. Nakandakare, J.T.
 517 Stefano, D. Giannella-Neto, M.L. Correa-Giannella, M. Passarelli, Advanced glycated albumin
 518 isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene
 519 expression impairing ABCA-1-mediated reverse cholesterol transport, Diabetes Metab Res Rev
 520 29(1) (2013) 66-76.
 521 [22] M. Valiyaveetil, N. Kar, M.Z. Ashraf, T.V. Byzova, M. Febbraio, E.A. Podrez, Oxidized high-
 522 density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI, Blood
 523 111(4) (2008) 1962-71.
 524 [23] G. Silbernagel, B. Schottker, S. Appelbaum, H. Scharnagl, M.E. Kleber, T.B. Grammer, A.
 525 Ritsch, U. Mons, B. Holleczek, G. Goliash, A. Niessner, B.O. Boehm, R.B. Schnabel, H. Brenner,
 526 S. Blankenberg, U. Landmesser, W. März, High-density lipoprotein cholesterol, coronary artery
 527 disease, and cardiovascular mortality, Eur Heart J 34(46) (2013) 3563-71.
 528 [24] D. Saleheen, R. Scott, S. Javad, W. Zhao, A. Rodrigues, A. Picataggi, D. Lukmanova, M.L.
 529 Mucksavage, R. Luben, J. Billheimer, J.J. Kastelein, S.M. Boekholdt, K.T. Khaw, N. Wareham,
 530 D.J. Rader, Association of HDL cholesterol efflux capacity with incident coronary heart disease
 531 events: a prospective case-control study, Lancet Diabetes Endocrinol 3(7) (2015) 507-13.

[25] E.S. Parra, N.B. Panzoldo, V.H. Zago, D.Z. Scherrer, F. Alexandre, J. Bakkarat, V.S. Nunes, E.R. Nakandakare, E.C. Quintao, W. Nadruz, Jr., E.C. de Faria, A.C. Sposito, HDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk, *PLoS One* 9(12) (2014) e114212.

[26] M. de la Llera Moya, F.C. McGillicuddy, C.C. Hinkle, M. Byrne, M.R. Joshi, V. Nguyen, J. Tabita-Martinez, M.L. Wolfe, K. Badellino, L. Pruscino, N.N. Mehta, B.F. Asztalos, M.P. Reilly, Inflammation modulates human HDL composition and function in vivo, *Atherosclerosis* 222(2) (2012) 390-4.

[27] T. Arai, S. Yamashita, K. Hirano, N. Sakai, K. Kotani, S. Fujioka, S. Nozaki, Y. Keno, M. Yamane, E. Shinohara, Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity, *Arterioscler Thromb* 14(7) (1994) 1129-36.

[28] C.F. Ebenbichler, M. Laimer, S. Kaser, A. Ritsch, A. Sandhofer, H. Weiss, F. Aigner, J.R. Patsch, Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women, *Arterioscler Thromb Vasc Biol* 22(9) (2002) 1465-9.

[29] C.P.J. Talbot, J. Plat, P.J. Joris, M. Konings, Y.H.A.M. Kusters, C.G. Schalkwijk, A. Ritsch, R.P. Mensink, HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men, *Atherosclerosis* 274 (2018) 23-28.

[30] B. Shao, C. Tang, A. Sinha, P.S. Mayer, G.D. Davenport, N. Brot, M.N. Oda, X.Q. Zhao, J.W. Heinecke, Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase, *Circ Res* 114(11) (2014) 1733-42.

[31] L.H. Bogl, S.M. Kaye, J.T. Ramo, A.J. Kangas, P. Soininen, A. Hakkarainen, J. Lundbom, N. Lundbom, A. Ortega-Alonso, A. Rissanen, M. Ala-Korpela, J. Kaprio, K.H. Pietilainen, Abdominal obesity and circulating metabolites: A twin study approach, *Metabolism* 65(3) (2016) 111-21.

[32] K. Bhaskaran, I. Dos-Santos-Silva, D.A. Leon, I.J. Douglas, L. Smeeth, Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK, *Lancet Diabetes Endocrinol* (2018).

[33] L.S. Carvalho, V.W. Virginio, N.B. Panzoldo, V.N. Figueiredo, S.N. Santos, R.G. Modolo, J.M. Andrade, E.S.J.C. Quinaglia, W. Nadruz-Junior, E.C. de Faria, A.C. Sposito, G. Brasilia Heart Study, Elevated CETP activity during acute phase of myocardial infarction is independently associated with endothelial dysfunction and adverse clinical outcome, *Atherosclerosis* 237(2) (2014) 777-83.

[34] A. Pirillo, A.L. Catapano, G.D. Norata, HDL in infectious diseases and sepsis, *Handb Exp Pharmacol* 224 (2015) 483-508.

[35] A. Kontush, S. Chantepie, M.J. Chapman, Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress, *Arterioscler Thromb Vasc Biol* 23(10) (2003) 1881-8.

[36] F. Santilli, N. Vazzana, R. Liani, M.T. Guagnano, G. Davi, Platelet activation in obesity and metabolic syndrome, *Obes Rev* 13(1) (2012) 27-42.

Figure 1. 3D surface plot showing the association between BMI, cIMT, and HDL variables. This surface plot displays an image based on the relationship between the BMI and HDL variables as predictors on the x- and y-axes and a continuous surface that represents the cIMT values on the z-axis. The peak on the plot corresponds with the yellow color and the highest value obtained to cIMT using the combination of X and Y that produce the maxima cIMT, which occurs at approximately 0.8mm. The valley corresponds with blue color and the combination of X and Y that produce the minima cIMT. Figure 1A, HDL-C values. Figure 1B, HDL size. Figure 1C, CEC values. Figure 1D, antioxidant activity of HDL. HDL-C, high-density lipoprotein cholesterol in mg/dL. BMI, body mass index in kg/m^2 . CEC is expressed as a percentage of efflux in the sample, normalized to a reference sample. Antioxidant activity is expressed in % as inhibition of LDL oxidation in the presence of each subject's HDL oxidation.

Figure 2. Polynomial splines showing the associations between BMI, cIMT and HDL variables. 2A, CEC according to BMI values. 2B, Antioxidant activity according to BMI values. 2C, compound variable (Z-Efflux + Z-Antioxidant activity) according to BMI values. 2D, cIMT values according to compound variable (Z-Efflux + Z-Antioxidant activity). Gray shading indicates 95% confidence intervals.

602 **Table 1.** Clinical characteristics according to BMI groups

	BMI categories (kg/m ²)			<i>p-value</i>
	<22	22-24.99	25-30	
Sample size	186	264	449	
BMI, kg/m²	20.6 (1.8)	23.6 (1.6) ^a	28 (4.6) ^{b,c}	<0.0001
Waist circumference, cm	68 (9)	75 (11) ^a	94 (19) ^{b,c}	<0.0001
Age, yr	38 (24)	45.5 (26) ^a	54 (16) ^b	0.003
Male sex, %	43.5	44.7	39.6	0.369
Hypertension, %	28.6	31.3	28.3	0.915
Glucose, mg/dL	81 (12.0)	86 (14.0) ^a	105 (62.0) ^{b,c}	<0.0001
Insulin, μU/mL	3.0 (2.5)	4.7 (4.9) ^a	10.2 (8.2) ^{b,c}	<0.0001
HOMA2 % β	61.9 (38.2)	61.3 (49.4)	64.9 (51.3) ^{b,c}	0.008
HOMA2 %S	241.7 (210.3)	161.2 (183.5)	68.8 (62.5) ^{b,c}	<0.0001
HOMA2-IR	0.46 (0.4)	0.51 (0.5)	0.66 (0.5) ^{b,c}	<0.0001
CRP, mg/dL	0.42 (0.9)	0.70 (1.1)	0.51 (1.0)	0.453
Triglycerides, mg/dL	66 (34)	81 (46) ^a	118 (87) ^{b,c}	<0.0001
LDL-C, mg/dL	95 (40)	104 (34) ^a	107 (42) ^b	<0.0001
Total cholesterol, mg/dL	175 (53)	181 (50)	187 (55) ^{b,c}	< 0.0001
ApoA-I, mg/dL	148 (53)	142 (46)	137 (38) ^{b,c}	<0.0001
ApoB, mg/dL	72 (23)	81 (27) ^a	90 (31) ^b	<0.0001
HDL-C, mg/dL	63 (29)	52 (30) ^a	45 (19) ^{b,c}	<0.0001

cIMT, mm	0.55 (0.20)	0.60 (0.20) ^a	0.70 (0.24) ^{b,c}	< 0.0001
-----------------	-------------	--------------------------	----------------------------	----------

603

604 All continuous variables are expressed as medians and interquartile ranges, and categorical
605 variables as percentages. Comparisons between groups were analyzed with Jonckheere–
606 Terpstra’s for ordered alternatives with pairwise comparisons, or Chi-Square test for the
607 categorical variables. To convert the values for glucose to millimoles per liter, divide by 18.
608 To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the
609 values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for
610 triglycerides to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI
611 >25 vs 22 – 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629 **Table 2.** Subgroup clinical characteristics according to BMI groups

BMI categories (kg/m2)					
	<22	22-24.99	25-30	<i>p-value</i>	
Sample size	34	47	20		
BMI, kg/m ²		20.0 (2.5)	23.5 (1.6) ^a	26.7 (2.55) ^{b,c}	<0.0001
Waist circumference, cm		65.0 (7.0)	75.5 (13.2) ^a	84.0 (10.5) ^{b,c}	<0.0001
Age, yr		42 (21)	39 (20.7)	47 (9.5)	0.24
Male sex, %		33.7	46.5	19.8	0.47
Glucose, mg/dL		80.0 (8.0)	83.0 (9.2)	86.0 (11.5) ^b	0.012
Insulin, μU/mL		2.5 (2.0)	4.3 (4.0) ^a	5.8 (6.0) ^{b,c}	<0.0001
HOMA2 % β		58.4 (37.8)	69.0 (45.9)	84.9 (38.7) ^b	<0.0001
HOMA2 %S		303.2 (261.6)	228.2 (221.9) ^a	148.2 (75.1) ^{b,c}	<0.0001
HOMA2-IR		0.3 (0.3)	0.4 (0.5) ^a	0.7 (0.5) ^{b,c}	<0.0001
CRP, mg/dL		0.9 (1.5)	0.71 (1.2)	0.6 (1.2)	0.51
Triglycerides, mg/dL		57.0 (27.2)	70.0 (29.0)	123.5 (72.7) ^{b,c}	<0.0001
LDL-C, mg/dL		98.0 (30.5)	100.0 (34.0)	101.0 (28.5)	0.57
Total cholesterol, mg/dL		181.0 (48.7)	169.0 (42.0)	173.0 (34.5)	0.13
ApoA-I, mg/dL		176.0 (61.2)	147.0 (53.0)	111.0 (57.2) ^{b,c}	<0.0001
ApoB, mg/dL		73.7 (24.3)	81.3 (26.1)	81.7 (22.3) ^b	0.04
HDL-C, mg/dL		72.5 (39.0)	49.0 (52.0) ^a	32.5 (15.0) ^{b,c}	<0.0001
cIMT, mm		0.55 (0.2)	0.58 (0.2)	0.67 (0.5)	0.05

630

631 All continuous variables are expressed as medians and interquartile ranges, and categorical
 632 variables as percentages. Comparisons between groups were analyzed with Jonckheere–
 633 Terpstra’s for ordered alternatives with pairwise comparisons, or Chi-Square test for the
 634 categorical variables. To convert the values for glucose to millimoles per liter, divide by 18.
 635 To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the
 636 values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for
 637 triglycerides to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI
 638 >25 vs 22 – 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656 **Table 3.** HDL characterization

	BMI categories (kg/m²)			
	<22	22-24.99	25-30	<i>p-value</i>
Sample size	34	47	20	
Total mass, mg/dL	198.8 (91)	182.3 (98)	155 (99) ^c	0.024
Triglycerides, mg/dL	9.8 (6.0)	7.8 (4.0)	8.3 (6)	0.047
Free cholesterol, mg/dL	8.0 (6.0)	6.3 (4.0) ^a	5.3 (3.0) ^c	0.001
Cholesteryl ester, mg/dL	60.1 (35)	52.9 (46)	39.7 (26) ^c	0.004
Phospholipids, mg/dL	35.1 (19)	29.2 (14) ^a	24.7 (13) ^c	<0.0001
ApoA-I, mg/dL	86.1 (40)	86.1 (48)	76.9 (39)	0.578
Total proteins, mg/dL	135.5 (71.5)	143.6 (74)	147.0 (54.0)	0.777
HDL size, nm	7.9 (0.9)	7.8 (0.9)	7.6 (0.8) ^{b,c}	<0.0001
Zeta potential, mV	-7.7 (5)	-6.4 (4)	-7.8 (9)	0.297
CETP, %	10.1 (6.4)	10.6 (7.3)	10.7 (6.3)	0.612
PLTP, μmol PC/mL/h	5.7 (2.9)	6.0 (3.2)	5.4 (3.5)	0.338
LCAT, nmol CE/mL/h	17.4 (15)	16.6 (12)	16.9 (19)	0.454
LPL, μmol FFA/mL/h	4.0 (3.4)	3.7 (3.7)	3.2 (2.9)	0.157
HL, μmol FFA/mL/h	4.9 (4.0)	5.8 (4.4)	5.8 (4.5)	0.440
PON/HDL-C, (mmol/min)/(mg/dL)	0.40 (0.5)	0.50 (0.7) ^a	0.54 (0.7) ^c	<0.001

657

658 All continuous variables are expressed as medians and interquartile ranges. To convert values
659 for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides
660 to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI >25 vs 22 –
661 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686 Table 4. Linear regression analyses between HDL functions and cIMT

Independent variable	Unstandardized β	Standardized β	Lower CI 95%	Upper CI 95%	p-value
Antioxidant activity					
Unadjusted					
Adjusted ^a	-0.001	-0.153	-0.003	0.000	0.128
	-0.002	-0.196	-0.003	0.000	0.038
CEC					
Unadjusted	-0.016	-0.260	-0.028	-0.004	0.009
Adjusted ^a	-0.012	-0.188	-0.023	0.000	0.047
PON/HDL-C					
Unadjusted	-0.010	-0.063	-0.079	0.024	0.301
Adjusted ^a	-0.045	-0.061	-0.071	0.019	0.254
Anti-inflammatory activity					
Unadjusted	0.000	-0.043	-0.003	0.002	0.676
Adjusted ^a	0.000	-0.004	-0.002	0.002	0.963
HDL-mediated platelet inhibition					
Unadjusted	0.002	0.164	0.000	0.004	0.120
Adjusted ^a	0.002	0.177	0.000	0.004	0.068

^b Adjusted for age, sex, BMI, HDL-C and insulin. In order to compare effects across different HDL functions we provided the standardized coefficients.

687

688

689

690

A.

B.

C.

D.

A Smoothing spline with 3 df selected by cross validation; $R^2 = 0.18$

B Smoothing spline with 3 df selected by cross validation; $R^2 = 0.12$

C Smoothing spline with 2 df selected by cross validation; $R^2 = 0.05$

D Smoothing spline with 4 df selected by cross validation; $R^2 = 0.25$